REVOTAR BIOPHARMACEUTICALS GRANTED ORPHAN-DRUG DESIGNATION

Revotar Biopharmaceuticals AG (Revotar) announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has granted orphan-drug designation to Revotar's pan-selectin antagonist bimosiamose disodium for the treatment of acute lung injury.

BioSpace

(http://www.biospace.com/news_story.cfm?StoryID=20386220&full=1)